The median overall survival was 38.21 months with radium-223 plus enzalutamide and 32.62 months with enzalutamide alone. For patients with metastatic castration-resistant prostate cancer (mCRPC) with ...

Patients treated with Xofigo-Xtandi experienced a 5.6-month boost to median OS over those treated with Xtandi alone.

Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases ...

Mayo Clinic in Jacksonville, Fla., offers a minimally invasive procedure to stabilize bones weakened by metastatic cancer, a technique available at few U.S. centers. The photodynamic bone ...

Bone marrow metastasis (BMM) from non-hematolymphoid malignancies with resultant cytopenia (s) can mimic primary hematolymphoid disorders. This study aimed to investigate the clinical and pathological ...